192 related articles for article (PubMed ID: 23518609)
1. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models.
Vincenzi F; Targa M; Corciulo C; Tabrizi MA; Merighi S; Gessi S; Saponaro G; Baraldi PG; Borea PA; Varani K
Pain; 2013 Jun; 154(6):864-73. PubMed ID: 23518609
[TBL] [Abstract][Full Text] [Related]
2. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
4. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
5. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
Curto-Reyes V; Llames S; Hidalgo A; Menéndez L; Baamonde A
Br J Pharmacol; 2010 Jun; 160(3):561-73. PubMed ID: 20233215
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.
Klauke AL; Racz I; Pradier B; Markert A; Zimmer AM; Gertsch J; Zimmer A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):608-20. PubMed ID: 24210682
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
[TBL] [Abstract][Full Text] [Related]
8. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.
Hsieh GC; Pai M; Chandran P; Hooker BA; Zhu CZ; Salyers AK; Wensink EJ; Zhan C; Carroll WA; Dart MJ; Yao BB; Honore P; Meyer MD
Br J Pharmacol; 2011 Jan; 162(2):428-40. PubMed ID: 20880025
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia.
Kalliomäki J; Annas P; Huizar K; Clarke C; Zettergren A; Karlsten R; Segerdahl M
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):212-8. PubMed ID: 23324098
[TBL] [Abstract][Full Text] [Related]
11. Effects of Se-phenyl thiazolidine-4-carboselenoate on mechanical and thermal hyperalgesia in brachial plexus avulsion in mice: mediation by cannabinoid CB1 and CB2 receptors.
Del Fabbro L; Borges Filho C; Cattelan Souza L; Savegnago L; Alves D; Henrique Schneider P; de Salles HD; Jesse CR
Brain Res; 2012 Sep; 1475():31-6. PubMed ID: 22902772
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
13. TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice.
Vincenzi F; Targa M; Romagnoli R; Merighi S; Gessi S; Baraldi PG; Borea PA; Varani K
Neuropharmacology; 2014 Jun; 81():6-14. PubMed ID: 24486382
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
[TBL] [Abstract][Full Text] [Related]
15. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Kinsey SG; Mahadevan A; Zhao B; Sun H; Naidu PS; Razdan RK; Selley DE; Imad Damaj M; Lichtman AH
Neuropharmacology; 2011; 60(2-3):244-51. PubMed ID: 20849866
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.
Nelson DW; Frost JM; Tietje KR; Florjancic AS; Ryther K; Carroll WA; Dart MJ; Daza AV; Hooker BA; Grayson GK; Fan Y; Garrison TR; El-Kouhen OF; Yao B; Pai M; Chandran P; Zhu C; Hsieh GC; Meyer MD
Bioorg Med Chem Lett; 2012 Apr; 22(7):2604-8. PubMed ID: 22370265
[TBL] [Abstract][Full Text] [Related]
17. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC
Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671
[TBL] [Abstract][Full Text] [Related]
18. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
[TBL] [Abstract][Full Text] [Related]
19. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
Hohmann AG; Farthing JN; Zvonok AM; Makriyannis A
J Pharmacol Exp Ther; 2004 Feb; 308(2):446-53. PubMed ID: 14610224
[TBL] [Abstract][Full Text] [Related]
20. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].
La Rana G; Russo R; Campolongo P; Bortolato M; Mangieri RA; Cuomo V; Iacono A; Raso GM; Meli R; Piomelli D; Calignano A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1365-71. PubMed ID: 16510698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]